

**PROVIDER NOTIFICATION OF POLICY CRITERIA
CHANGE**

POLICY TITLE	POLICY NUMBER	CRITERIA CHANGE	MATERIAL AMENDMENT	EFFECTIVE DATE	LINK TO FULL POLICY
<p>Molecular Testing in the Management of Pulmonary Conditions</p>	<p>2017019</p>	<p>Percepta Genomic Sequencing Classifier removed from Policy as product no longer marketed. REVEAL Lung Nodule Characterization removed from Policy as company no longer in business:</p> <p>Plasma-based proteomic screening, including but not limited to Nodify XL2 (BDX-XL2) and Nodify CDT and REVEAL Lung Nodule Characterization (MagArray), in individuals with undiagnosed pulmonary nodules detected by computed tomography does not meet member benefit certificate Primary Coverage Criteria that there be scientific evidence of effectiveness in improving health outcomes.</p> <p>Gene expression profiling on bronchial brushings, including but not limited to Percepta Genomic Sequencing Classifier, in individuals with indeterminate bronchoscopy results from undiagnosed pulmonary nodules does not meet member benefit certificate primary coverage criteria that there be scientific evidence of effectiveness.</p>	<p>No</p>	<p>9/1/2026</p>	<p>https://secure.arkansasbluecross.com/members/report.aspx?policyNumber=2017019</p>